Butyrate as therapy for congenital chloride diarrhea

Phase 1

Completed

• Conditions: Congenital chloride diarrhea; Human Genetics and Inherited Disorders - Other human genetics and inherited disorders; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon; Diet and Nutrition - Other diet and nutrition disorders

• Registration Number: ACTRN12613000450718
• Lead Sponsor: Department of Pediatrics, University of Naples Federico II

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-04-19
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 7

Inclusion Criteria

All patients (age < 18 years) with diagnosis of congenital chloride diarrhea, will be considered eligible for the study.

Exclusion Criteria

Severe clinical conditions, concomitant presence of acute intestinal or extraintestinal infections, probiotics, non-steroideal anti-inflammatory drugs (NSAIDs), or antibiotics use in the last 4 weeks, chronic diseases (inflammatory bowel diseases, congenital motility disorders, food allergy, celiac disease, cystic fibrosis, immunodeficiency).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fecal chloride and sodium concentrations. [Measured on the fecal sample collected in the last 3 days of baseline week and week of treatment. Data obtained during the week of treatment were compared with that of previuos baseline week.]